State Key Laboratory of Biochemical Engineering and Key Laboratory of Biopharmaceutical Production & Formulation Engineering, PLA, Institute of Process Engineering, Chinese Academy of Sciences, Beijing 100190, PR China; University of Chinese Academy of Sciences, Beijing 100049, PR China.
State Key Laboratory of Biochemical Engineering and Key Laboratory of Biopharmaceutical Production & Formulation Engineering, PLA, Institute of Process Engineering, Chinese Academy of Sciences, Beijing 100190, PR China.
Carbohydr Polym. 2017 Jun 15;166:64-72. doi: 10.1016/j.carbpol.2017.02.058. Epub 2017 Feb 23.
This study aimed to investigate the effect of chitosan oligosaccharide (COS) conjugation on the immunogenicity of porcine circovirus type-2 (PCV2) vaccine. Two conjugates (PCV2-COS-1 and PCV2-COS-2) were designed by covalent conjugation of an inactivated PCV2 vaccine with COS, and administered to C57BL/6 mice three times at two-week intervals. The results indicate that, as compared to PCV2 alone group, the PCV2-COS conjugates remarkably enhanced both humoral and cellular immunity against PCV2 by promoting T lymphocyte proliferation and initiating a mixed Th1/Th2 response, including the elevated production of PCV-2 specific antibodies and up-regulated secretion of inflammatory cytokines. Noticeably, the immunization with PCV2-COS-1 conjugate displayed similar or even better immune-stimulating effects than that by PCV2/ISA206 (a commercialized adjuvant) and showed no infection or pathological signs at injection sites of the mice. Presumably, the covalent linkage of PCV2 vaccine to COS might be a viable strategy to increase the efficacy against PCV2-associated diseases.
本研究旨在探讨壳寡糖（COS）缀合对猪圆环病毒 2 型（PCV2）疫苗免疫原性的影响。通过将灭活的 PCV2 疫苗与 COS 共价缀合，设计了两种缀合物（PCV2-COS-1 和 PCV2-COS-2），并在两周的间隔内分三次给 C57BL/6 小鼠进行给药。结果表明，与单独的 PCV2 相比，PCV2-COS 缀合物通过促进 T 淋巴细胞增殖并引发混合 Th1/Th2 反应，显著增强了对 PCV2 的体液和细胞免疫应答，包括 PCV-2 特异性抗体的产生增加和炎症细胞因子的分泌上调。值得注意的是，PCV2-COS-1 缀合物的免疫接种显示出与 PCV2/ISA206（一种商业化佐剂）相似甚至更好的免疫刺激作用，并且在小鼠的注射部位没有感染或病理迹象。推测 PCV2 疫苗与 COS 的共价结合可能是提高针对 PCV2 相关疾病的疗效的可行策略。
